Tags

Type your tag names separated by a space and hit enter

Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
Pharmacol Ther 2008; 117(3):354-73P&T

Abstract

Hypertension, a prevalent risk factor for cardiovascular disease, frequently occurs in conjunction with metabolic disturbances and in particular with dyslipidaemia; such comorbidity presents in more than one-third of hypertensive patients. Moreover, hypertension and dyslipidaemia often manifest concomitantly in the clinical context of obesity and insulin resistance. In this setting, distinct metabolic anomalies may account for the development of both conditions, and may equally act to exacerbate their effects on vascular dysfunction. Significantly, hypertension and dyslipidaemia are linked mechanistically and may act in synergy at the arterial wall to enhance atherosclerosis. In this review, we identify potential mechanisms underlying the pathophysiological interaction between hypertension and dyslipidaemia at the cellular and molecular levels, and which may underlie elevated cardiovascular risk in obesity and insulin resistance. Finally, the clinical evidence supporting the beneficial effects of an integrated pharmacotherapeutic strategy to the reduction of cardiovascular risk in patients with insulin resistance, type 2 diabetes and the metabolic syndrome is critically discussed.

Authors+Show Affiliations

INSERM (National Institute for Health and Medical Research), Unité 551, Hôpital de la Pitié, Paris, F-75013, France. chapman@chups.jussieu.frNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18215759

Citation

Chapman, M John, and Andrei C. Sposito. "Hypertension and Dyslipidaemia in Obesity and Insulin Resistance: Pathophysiology, Impact On Atherosclerotic Disease and Pharmacotherapy." Pharmacology & Therapeutics, vol. 117, no. 3, 2008, pp. 354-73.
Chapman MJ, Sposito AC. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol Ther. 2008;117(3):354-73.
Chapman, M. J., & Sposito, A. C. (2008). Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacology & Therapeutics, 117(3), pp. 354-73. doi:10.1016/j.pharmthera.2007.10.004.
Chapman MJ, Sposito AC. Hypertension and Dyslipidaemia in Obesity and Insulin Resistance: Pathophysiology, Impact On Atherosclerotic Disease and Pharmacotherapy. Pharmacol Ther. 2008;117(3):354-73. PubMed PMID: 18215759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. AU - Chapman,M John, AU - Sposito,Andrei C, Y1 - 2007/12/14/ PY - 2007/09/28/received PY - 2007/10/01/accepted PY - 2008/1/25/pubmed PY - 2008/6/27/medline PY - 2008/1/25/entrez SP - 354 EP - 73 JF - Pharmacology & therapeutics JO - Pharmacol. Ther. VL - 117 IS - 3 N2 - Hypertension, a prevalent risk factor for cardiovascular disease, frequently occurs in conjunction with metabolic disturbances and in particular with dyslipidaemia; such comorbidity presents in more than one-third of hypertensive patients. Moreover, hypertension and dyslipidaemia often manifest concomitantly in the clinical context of obesity and insulin resistance. In this setting, distinct metabolic anomalies may account for the development of both conditions, and may equally act to exacerbate their effects on vascular dysfunction. Significantly, hypertension and dyslipidaemia are linked mechanistically and may act in synergy at the arterial wall to enhance atherosclerosis. In this review, we identify potential mechanisms underlying the pathophysiological interaction between hypertension and dyslipidaemia at the cellular and molecular levels, and which may underlie elevated cardiovascular risk in obesity and insulin resistance. Finally, the clinical evidence supporting the beneficial effects of an integrated pharmacotherapeutic strategy to the reduction of cardiovascular risk in patients with insulin resistance, type 2 diabetes and the metabolic syndrome is critically discussed. SN - 0163-7258 UR - https://www.unboundmedicine.com/medline/citation/18215759/Hypertension_and_dyslipidaemia_in_obesity_and_insulin_resistance:_pathophysiology_impact_on_atherosclerotic_disease_and_pharmacotherapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(07)00232-X DB - PRIME DP - Unbound Medicine ER -